Betaloc solution intravenously 1mg ml ampoules 5ml N5
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Metoprolol
Composition
1 ml of 1 amp. Metoprolol tartrate 1 mg 5 mg. Excipients: sodium chloride, water d / and.
Pharmacological effect
In patients with myocardial infarction, intravenous administration of metoprolol reduces chest pain and reduces the risk of atrial fibrillation and atrial flutter. Intravenous administration of metoprolol at the first symptoms (within 24 hours after the onset of the first symptoms) reduces the risk of myocardial infarction. Early initiation of treatment with metoprolol leads to an improvement in the further prognosis of the treatment of myocardial infarction. Achieved a decrease in heart rate (HR) with paroxysmal tachycardia and atrial fibrillation (flutter). Metoprolol - & # 946 .1 is an adrenoblocker that blocks the & # 946 .1 receptors at doses significantly lower than the doses required to block the # 946 .2 receptors. Metoprolol has an insignificant membrane-stabilizing effect and does not exhibit partial agonist activity. Metoprolol reduces or inhibits the agonistic effect that catecholamines, which are formed during nervous and physical stress, have on cardiac activity. This means that metoprolol has the ability to prevent an increase in heart rate, minute volume, and increased myocardial contractility, as well as an increase in blood pressure caused by the release of catecholamines. Patients with symptoms of obstructive pulmonary disease can, if necessary, be prescribed metoprolol in combination with & # 946 .2-adrenomimetics. When used together with & # 946 .2- adrenomimetics, Betaloc in therapeutic doses has less effect on bronchodilatation caused by & # 946 .2- adrenergic mimetics than non-selective & # 946. -Adrenoblockers. Metoprolol to a lesser extent than non-selective & # 946.-Adrenergic blockade. We influence the production of insulin and carbohydrate metabolism. The effect of the drug Betaloc on the reaction of the cardiovascular system in hypoglycemia is much less pronounced compared with non-selective & .946 adrenergic blockers. Improving the quality of life during treatment with the drug Betaloc was observed in patients after myocardial infarction.
Indications
- supraventricular tachycardia - prevention and treatment of myocardial ischemia, tachycardia and pain during myocardial infarction or suspicion of it.
Contraindications
- atrioventricular block II and III degree - heart failure in the stage of decompensation - clinically significant sinus bradycardia - sick sinus syndrome, - cardiogenic shock - pronounced disorders of the peripheral circulation - arterial hypotension - patients with acute myocardial infarction per 45 hours per hour per hour per arterial hypotension per patient per month less than 45 beats per hour per hour. PQ more than 0.24 seconds or systolic blood pressure less than 100 mm Hg - with serious peripheral vascular diseases with the threat of gangrene - patients receiving 946. -Adrenergic blockers, intravenous administration of blockers of “slow” calcium channels like verapamil - age up to 18 years (efficacy and safety not established) - known hypersensitivity to metoprolol and its components or to other. # -Adrenoblockers. With care: atrioventricular block I degree, Prinzmetal angina pectoris, chronic obstructive pulmonary disease (pulmonary emphysema, chronic obstructive bronchitis, bronchial asthma), diabetes mellitus, severe renal failure.
Use during pregnancy and lactation
Like most drugs, Betaloc should not be prescribed during pregnancy and during breastfeeding, except in cases where the expected benefit to the mother outweighs the potential risk to the fetus. Like other antihypertensive drugs, & # 946. -Adrenergic blockers can cause side effects, for example, bradycardia in the fetus, newborns or babies who are breastfed, and therefore you should be especially careful when administering & .946 -adrenergic blockers in the last trimester of pregnancy and immediately before birth. Lactation period: The amount of metoprolol excreted in breast milk and & # 946 .- a blocking effect in a baby who is breastfed (when the mother takes metoprolol in therapeutic doses) is insignificant.
Dosage and administration
Supraventricular tachycardia. Begin administration with 5 mg (5 ml) of Betaloc at a rate of 1–2 mg / min. You can repeat the introduction at a 5-minute interval to achieve a therapeutic effect. Usually, the total dose is 10-15 mg (10-15 ml). The recommended maximum dose for intravenous administration is 20 mg (20 ml).Prevention and treatment of myocardial ischemia, tachycardia and pain in myocardial infarction or suspicion of it. Intravenous 5 mg (5 ml) of the drug. You can repeat the introduction with a 2-minute interval, the maximum dose - 15 mg (15 ml). 15 minutes after the last injection, metoprolol is prescribed for oral administration in a dose of 50 mg (Betaloc) every 6 hours for 48 hours. Impaired renal function There is no need to adjust the dose in patients with impaired renal function. Impaired liver function Usually, due to the low degree of association with plasma proteins, dose adjustment is not required. However, in severe liver dysfunction (in patients with porcaval anastomosis), a dose reduction may be required. Elderly age There is no need to adjust the dose in elderly patients. Children experience of the use of the drug Betaloc in children is limited
Side effects
Betaloc is well tolerated by patients and the side effects are mostly mild and reversible. As a result of clinical studies or when using the drug Betaloc (metoprolol tartrate), the following undesirable side effects have been described in clinical practice. In many cases, a causal relationship with treatment with the drug Betaloc has not been established. The following criteria were used to assess the frequency of cases: very often (> 10%), often (1-9.9%), infrequently (0.1-0.9%), rarely (0.01-0.09%) and very rarely (less than 0.01%). Cardiovascular system Often: bradycardia, postural disorders (very rarely accompanied by fainting), cold extremities, palpitations. Infrequently: a temporary increase in the symptoms of heart failure, cardiogenic shock in patients with acute myocardial infarction. AV blockade I degree. Seldom: other disturbances of cordial conductivity, arrhythmias. Very rare: gangrene in patients with previous severe disorders of the peripheral circulation. CNS Very often: increased fatigue. Often: dizziness, headache. Rarely: increased nervous irritability, anxiety, impotence / sexual dysfunction. Infrequently: paresthesias, convulsions, depression, weakening of attention, drowsiness or insomnia, nightmares. Very rarely: amnesia / memory impairment, depression, gastrointestinal hallucinations Often: nausea, abdominal pain, diarrhea, constipation. Infrequently: vomiting. Rarely: dry mouth. Liver Rare: abnormal liver function.Skin Infrequently: rash (in the form of urticaria), excessive sweating. Rarely: hair loss. Very rare: photosensitivity, exacerbation of psoriasis. Respiratory Organs Often: shortness of breath on physical exertion. Infrequently: bronchospasm in patients with bronchial asthma. Rarely: rhinitis. Sense organs Rarely: visual impairment, dryness and / or irritation of the eyes, conjunctivitis. Very rarely: tinnitus, taste disturbances. Metabolism Infrequent: weight gain. On the part of the musculoskeletal system: Very rare: arthralgia Blood Very rare: thrombocytopenia.
special instructions
Betaloc is well tolerated by patients and the side effects are mostly mild and reversible. As a result of clinical studies or when using the drug Betaloc (metoprolol tartrate), the following undesirable side effects have been described in clinical practice. In many cases, a causal relationship with treatment with the drug Betaloc has not been established. The following criteria were used to assess the frequency of cases: very often (> 10%), often (1-9.9%), infrequently (0.1-0.9%), rarely (0.01-0.09%) and very rarely (less than 0.01%). Cardiovascular system Often: bradycardia, postural disorders (very rarely accompanied by fainting), cold extremities, palpitations. Infrequently: a temporary increase in the symptoms of heart failure, cardiogenic shock in patients with acute myocardial infarction. AV blockade I degree. Seldom: other disturbances of cordial conductivity, arrhythmias. Very rare: gangrene in patients with previous severe disorders of the peripheral circulation. CNS Very often: increased fatigue. Often: dizziness, headache. Rarely: increased nervous irritability, anxiety, impotence / sexual dysfunction. Infrequently: paresthesias, convulsions, depression, weakening of attention, drowsiness or insomnia, nightmares. Very rarely: amnesia / memory impairment, depression, gastrointestinal hallucinations Often: nausea, abdominal pain, diarrhea, constipation. Infrequently: vomiting. Rarely: dry mouth. Liver Rare: abnormal liver function. Skin Infrequently: rash (in the form of urticaria), excessive sweating. Rarely: hair loss. Very rare: photosensitivity, exacerbation of psoriasis. Respiratory Organs Often: shortness of breath on physical exertion. Infrequently: bronchospasm in patients with bronchial asthma. Rarely: rhinitis.Sense organs Rarely: visual impairment, dryness and / or irritation of the eyes, conjunctivitis. Very rarely: tinnitus, taste disturbances. Metabolism Infrequent: weight gain. On the part of the musculoskeletal system: Very rare: arthralgia Blood Very rare: thrombocytopenia.